Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Itacitinib + Parsaclisib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Itacitinib | INCB039110|INCB-039110|INCB 039110 | JAK1 Inhibitor 9 | Itacitinib (INCB039110) is a selective inhibitor of Janus kinase 1 (JAK1), which may inhibit cell proliferation (PMID: 25605813, PMID: 32861662). | |
Parsaclisib | INCB050465|INCB 50465|INCB-50465|INCB50465|WHO 10589 | PIK3CD inhibitor 27 | Parsaclisib (INCB050465) inhibits PI3K-delta, blocking activation of AKT signaling pathway and leading to apoptosis of PIK3CD expressing tumor cells (PMID: 31749910). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02018861 | Phase I | Itacitinib Itacitinib + Parsaclisib Bendamustine Rituximab Carboplatin + Etoposide + Ifosfamide Parsaclisib | A Phase 1, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 Monotherapy and in Combination With INCB039110 in Subjects With Previously Treated B-Cell Malignancies | Completed | USA | 0 |
NCT02559492 | Phase I | Epacadostat + Itacitinib Itacitinib + Parsaclisib | INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors | Terminated | USA | 0 |
NCT04509700 | Phase II | Parsaclisib Itacitinib + Parsaclisib | Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) | Recruiting | USA | ITA | GBR | FRA | ESP | BEL | AUT | 10 |